Deficient associative learning in drug-naive first-episode schizophrenia: Results obtained using a new visual within-subjects learned irrelevance paradigm

Behavioural Brain Research

Volumn 193, Issue 1, 2008, Pages 101-107

  Orosz, Ariane T ^a,b,e   Feldon, Joram ^a   Gal, Gilad ^c   Simon, Andor E ^d   Cattapan Ludewig, Katja ^b,e  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^d Specialised Outpatient Service for Early Psychosis   (Switzerland)

^e Aargau Canton AG   (Switzerland)

Author keywords

Drug free; First episode schizophrenia; Information processing; Latent inhibition; Learned irrelevance; Repeated measurements; Translational paradigm; Within subject design

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROL GROUP; DEPRESSION; FEMALE; FOLLOW UP; HUMAN; MALE; MENTAL DISEASE; PRIORITY JOURNAL; SCHIZOPHRENIA; STATE DEPENDENT LEARNING;

ADOLESCENT; ADULT; ASSOCIATION LEARNING; ATTENTION; CONDITIONING, CLASSICAL; EXTINCTION, PSYCHOLOGICAL; FEMALE; FIELD DEPENDENCE-INDEPENDENCE; FOLLOW-UP STUDIES; HUMANS; INHIBITION (PSYCHOLOGY); MALE; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; RECOGNITION (PSYCHOLOGY); SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; VISUAL PERCEPTION;

EID: 48049097055     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2008.04.025     Document Type: Article

References (36)

1. Baruch I., Hemsley D.R., and Gray J.A. Differential performance of acute and chronic schizophrenics in a latent inhibition task. J Nerv Ment Dis 176 (1988) 598-606
2. Bleuler E. Dementia praecox oder die Gruppe der Schizophrenien. In: Achaffenburg G. (Ed). Handbuch der Psychiatrie (1911), Franz Deuticke Verlag, Leipzig, Wien
3. Braff D.L. Information processing and attention dysfunctions in schizophrenia. Schizophr Bull 19 (1993) 233-259
4. Chang T., Meyer U., Feldon J., and Yee B.K. Disruption of the US pre-exposure effect and latent inhibition in two-way active avoidance by systemic amphetamine in C57BL/6 mice. Psychopharmacology (Berl) 191 (2007) 211-221
5. Della Casa V., Hofer I., Weiner I., and Feldon J. Effects of smoking status and schizotypy on latent inhibition. J Psychopharmacol 13 (1999) 45-57
6. Gal G., Mendlovic S., Bloch Y., Beitler G., Levkovitz Y., Young A.M., et al. Learned irrelevance is disrupted in first-episode but not chronic schizophrenia patients. Behav Brain Res 159 (2005) 267-275
7. Ginton A., Urca G., and Lubow R.E. The effects of preexposure to a nonattended stimulus on subsequent learning: latent inhibition in adults. Bull Psychonomic Soc 5 (1975) 5-8
8. Grace A.A. The depolarization block hypothesis of neuroleptic action: implications for the etiology and treatment of schizophrenia. J Neural Transm Suppl 36 (1992) 91-131
9. Gray J.A., Feldon J., Rawlins J.N.P., Hemsley D.R., and Smith A.D. The neuropsychology of schizophrenia. Behav Brain Sci 14 (1991) 1-84
10. Gray J.A., Joseph M.H., Hemsley D.R., Young A.M., Warburton E.C., Boulenguez P., et al. The role of mesolimbic dopaminergic and retrohippocampal afferents to the nucleus accumbens in latent inhibition: implications for schizophrenia. Behav Brain Res 71 (1995) 19-31
11. Gray N.S., Hemsley D.R., and Gray J.A. Abolition of latent inhibition in acute, but not chronic schizophrenia. Neurol Psychiatr Brain Res 1 (1992) 83-89
12. Gray N.S., Pickering A.D., Hemsley D.R., Dawling S., and Gray J.A. Abolition of latent inhibition by a single 5 mg dose of d-amphetamine in man. Psychopharmacology (Berl) 107 (1992) 425-430
13. Gray N.S., Pilowsky L.S., Gray J.A., and Kerwin R.W. Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET. Schizophr Res 17 (1995) 95-107
14. Gray N.S., and Snowden R.J. The relevance of irrelevance to schizophrenia. Neurosci Biobehav Rev 29 (2005) 989-999
15. Gründer G., Vernaleken I., Müller M.J., Davids E., Heydari N., Buchholz H.G., et al. Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology 28 (2003) 787-794
16. Heinrichs R.W. In search of madness: schizophrenia and neuroscience (2001), Oxford University Press, New York
17. Johnstone E.C., Crow T.J., Frith C.D., Carney M.W., and Price J.S. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1 (1978) 848-851
18. Kay S.R., Fiszbein A., and Opler L.A. The Positive And Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13 (1987) 261-276
19. Leumann L., Feldon J., Vollenweider F.X., and Ludewig K. Effects of typical and atypical antipsychotics on prepulse inhibition and latent inhibition in chronic schizophrenia. Biol Psychiatry 52 (2002) 729-739
20. Lieberman J.A., Kane J.M., and Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 91 (1987) 415-433
21. Lubow R.E., and Gewirtz J.C. Latent inhibition in humans: data, theory, and implications for schizophrenia. Psychol Bull 117 (1995) 87-103
22. Lubow R.E., Kaplan O., Abramovich P., Rudnick A., and Laor N. Visual search in schizophrenia: latent inhibition and novel pop-out effects. Schizophr Res 45 (2000) 145-156
23. Lubow R.E., and MOORE A.U. Latent inhibition: the effect of nonreinforced pre-exposure to the conditional stimulus. J Comp Physiol Psychol 52 (1959) 415-419
24. Nuechterlein K.H., and Dawson M.E. Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr Bull 10 (1984) 160-203
25. Orosz A., Feldon J., Gal G., Simon A., and Cattapan-Ludewig K. Repeated measurements of learned irrelevance by a novel within-subject paradigm in humans. Behav Brain Res 180 (2007) 1-3
26. Overall J., and Gorham D. The Brief Psychiatric Rating Scale. Psychological Report 10 (1962) 799-812
27. Peleg-Raibstein D., Sydekum E., Russig H., and Feldon J. Withdrawal from continuous amphetamine administration abolishes latent inhibition but leaves prepulse inhibition intact. Psychopharmacology (Berl) 185 (2006) 226-239
28. Rascle C., Mazas O., Vaiva G., Tournant M., Raybois O., Goudemand M., et al. Clinical features of latent inhibition in schizophrenia. Schizophr Res 51 (2001) 149-161
29. Swerdlow N.R., Braff D.L., Hartston H., Perry W., and Geyer M.A. Latent inhibition in schizophrenia. Schizophr Res 20 (1996) 91-103
30. Swerdlow N.R., Stephany N., Wasserman L.C., Talledo J., Sharp R., and Auerbach P.P. Dopamine agonists disrupt visual latent inhibition in normal males using a within-subject paradigm. Psychopharmacology (Berl) 169 (2003) 314-320
31. Thornton J.C., Dawe S., Lee C., Capstick C., Corr P.J., Cotter P., et al. Effects of nicotine and amphetamine on latent inhibition in human subjects. Psychopharmacology (Berl) 127 (1996) 164-173
32. Vaitl D., Lipp O., Bauer U., Schüler G., Stark R., Zimmermann M., et al. Latent inhibition and schizophrenia: Pavlovian conditioning of autonomic responses. Schizophr Res 55 (2002) 147-158
33. Weiner I. The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology (Berl) 169 (2003) 257-297
34. Williams J.H., Wellman N.A., Geaney D.P., Cowen P.J., Feldon J., and Rawlins J.N. Reduced latent inhibition in people with schizophrenia: an effect of psychosis or of its treatment. Br J Psychiatry 172 (1998) 243-249
35. Wittchen HU, Pfister H. DIA-X interview. Frankfurt, Swets Test, 1997.
36. Young A.M., Kumari V., Mehrotra R., Hemsley D.R., Andrew C., Sharma T., et al. Disruption of learned irrelevance in acute schizophrenia in a novel continuous within-subject paradigm suitable for fMRI. Behav Brain Res 156 (2005) 277-288